Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available
NEWS 39	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS 40	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS 41	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 42	Feb 13	CANCERLIT is no longer being updated
NEWS 43	Feb 24	METADEX enhancements
NEWS 44	Feb 24	PCTGEN now available on STN
NEWS 45	Feb 24	TEMA now available on STN

```
NEWS 46  Feb 26  NTIS now allows simultaneous left and right truncation
NEWS 47  Feb 26  PCTFULL now contains images
NEWS 48  Mar 04  SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 49  Mar 19  APOLLIT offering free connect time in April 2003
NEWS 50  Mar 20  EVENTLINE will be removed from STN
NEWS 51  Mar 24  PATDPAFULL now available on STN
NEWS 52  Mar 24  Additional information for trade-named substances without
                 structures available in REGISTRY
NEWS 53  Mar 24  Indexing from 1957 to 1966 added to records in CA/CAPLUS

NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
              CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
              AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS INTER    General Internet Information
NEWS LOGIN    Welcome Banner and News Items
NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 10:28:06 ON 01 APR 2003

=> file polymers
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'APOLLIT' ENTERED AT 10:28:22 ON 01 APR 2003
COPYRIGHT (c) 2003 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 10:28:22 ON 01 APR 2003
COPYRIGHT (c) 2003 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 10:28:22 ON 01 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 10:28:22 ON 01 APR 2003
COPYRIGHT (c) 2003 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEN' ENTERED AT 10:28:22 ON 01 APR 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 10:28:22 ON 01 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'EMA' ENTERED AT 10:28:22 ON 01 APR 2003
```

```
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 10:28:22 ON 01 APR 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 10:28:22 ON 01 APR 2003
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'PASCAL' ENTERED AT 10:28:22 ON 01 APR 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PLASNEWS' ENTERED AT 10:28:22 ON 01 APR 2003
Copyright (C) 2003 Bill Communications, Inc. (BCI)

FILE 'PROMT' ENTERED AT 10:28:22 ON 01 APR 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 10:28:22 ON 01 APR 2003
COPYRIGHT (C) 2003 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 10:28:22 ON 01 APR 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'TEXTILETECH' ENTERED AT 10:28:22 ON 01 APR 2003
COPYRIGHT (C) 2003 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 10:28:22 ON 01 APR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:28:22 ON 01 APR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 10:28:22 ON 01 APR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WTEXTILES' ENTERED AT 10:28:22 ON 01 APR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s composition
  16 FILES SEARCHED...
L1     4583415 COMPOSITION

=> s l1 and (polysaccharide and ?amine)
LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'APOLLIT'
LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'BABS'
LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'CBNB'
LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'CEN'
LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'EMA'
LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'IFIPAT'
LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'JICST-EPLUS'
LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'PASCAL'
LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'PLASNEWS'
LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'PROMT'
LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'RAPRA'
  14 FILES SEARCHED...
LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'TEXTILETECH'
  16 FILES SEARCHED...
  18 FILES SEARCHED...
LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'WTEXTILES'
```

```
L2       26461 L1 AND (POLYSACCHARIDE AND ?AMINE)
Left truncation is not valid in the specified search field in the
specified file.  The term has been searched without left truncation.
Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID'
would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you
used a truncation symbol after a punctuation mark, the system may
interpret the truncation symbol as being at the beginning of a term.
Implied proximity is used in search fields indexed as single words,
for example, the Basic Index.

=> s l1 and (polysaccharide and polyamine)
L3        3258 L1 AND (POLYSACCHARIDE AND POLYAMINE)

=> s l3 and (alkyl or hydrophob? or amphiphil?)
L4        2816 L3 AND (ALKYL OR HYDROPHOB? OR AMPHIPHIL?)

=> s l4 and (nucleic or protein)
  15 FILES SEARCHED...
L5        1815 L4 AND (NUCLEIC OR PROTEIN)

=> s l5 and (dextran or arabinogalactan or pullulan or cellulose or cellobiose or
inulin or chitosan or alginate or hyaluron?)
  16 FILES SEARCHED...
L6        1616 L5 AND (DEXTRAN OR ARABINOGALACTAN OR PULLULAN OR CELLULOSE
               OR CELLOBIOSE OR INULIN OR CHITOSAN OR ALGINATE OR HYALURON?)

=> s l6 and (spermine or spermidine or polyethyleneimine)
L7         559 L6 AND (SPERMINE OR SPERMIDINE OR POLYETHYLENEIMINE)

=> s l7 and (biological or membrane)
L8         405 L7 AND (BIOLOGICAL OR MEMBRANE)

=> s l8 and biodegra?
L9         255 L8 AND BIODEGRA?

=> s l9 and (cell or transfect?)
  16 FILES SEARCHED...
L10        245 L9 AND (CELL OR TRANSFECT?)

=> s l10 and peptide
L11        220 L10 AND PEPTIDE

=> s l11 and (polynucleic or oligonucleotide or antisense)
L12        204 L11 AND (POLYNUCLEIC OR OLIGONUCLEOTIDE OR ANTISENSE)

=> s l12 and (fatty or oleic or glycol)
L13        203 L12 AND (FATTY OR OLEIC OR GLYCOL)

=> s l14 and (toxic or immunog?)
L14 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l13 and (toxic or immunog?)
L14         40 L13 AND (TOXIC OR IMMUNOG?)

=> dis l14 1-40 bib abs
COMMAND INTERRUPTED

If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.
```

```
=> index polymers
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       162.56     162.77

INDEX 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, EMA, IFIPAT, JICST-EPLUS, PASCAL,
      PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPIDS,
      WPINDEX, WTEXTILES' ENTERED AT 10:43:00 ON 01 APR 2003

20 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> dis hist

     (FILE 'HOME' ENTERED AT 10:28:06 ON 01 APR 2003)

     FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, EMA, IFIPAT, JICST-EPLUS,
     PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL,
     USPAT2, WPINDEX, WTEXTILES' ENTERED AT 10:28:22 ON 01 APR 2003
L1       4583415 S COMPOSITION
L2         26461 S L1 AND (POLYSACCHARIDE AND ?AMINE)
L3          3258 S L1 AND (POLYSACCHARIDE AND POLYAMINE)
L4          2816 S L3 AND (ALKYL OR HYDROPHOB? OR AMPHIPHIL?)
L5          1815 S L4 AND (NUCLEIC OR PROTEIN)
L6          1616 S L5 AND (DEXTRAN OR ARABINOGALACTAN OR PULLULAN OR CELLULOSE
L7           559 S L6 AND (SPERMINE OR SPERMIDINE OR POLYETHYLENEIMINE)
L8           405 S L7 AND (BIOLOGICAL OR MEMBRANE)
L9           255 S L8 AND BIODEGRA?
L10          245 S L9 AND (CELL OR TRANSFECT?)
L11          220 S L10 AND PEPTIDE
L12          204 S L11 AND (POLYNUCLEIC OR OLIGONUCLEOTIDE OR ANTISENSE)
L13          203 S L12 AND (FATTY OR OLEIC OR GLYCOL)
L14           40 S L13 AND (TOXIC OR IMMUNOG?)

     INDEX 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, EMA, IFIPAT, JICST-EPLUS,
     PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL,
     USPAT2, WPIDS, WPINDEX, WTEXTILES' ENTERED AT 10:43:00 ON 01 APR 2003

=> s l14
   9 FILES SEARCHED...
  14 FILES SEARCHED...
        40   FILE USPATFULL
  18 FILES SEARCHED...

   1 FILES HAVE ONE OR MORE ANSWERS,   20 FILES SEARCHED IN STNINDEX

L15 QUE L14

=> d rank
F1          40   USPATFULL


=> file f1
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         2.75     165.52

FILE 'USPATFULL' ENTERED AT 10:45:45 ON 01 APR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 1 Apr 2003 (20030401/PD)
```

FILE LAST UPDATED: 1 Apr 2003 (20030401/ED)
HIGHEST GRANTED PATENT NUMBER: US6543053
HIGHEST APPLICATION PUBLICATION NUMBER: US2003061649
CA INDEXING IS CURRENT THROUGH 1 Apr 2003 (20030401/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 1 Apr 2003 (20030401/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2003
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l14
        130658 TOXIC
           273 TOXICS
        130738 TOXIC
                  (TOXIC OR TOXICS)
         39419 IMMUNOG?
L16   40 L13 AND (TOXIC OR IMMUNOG?)

=> dis l16 1-40 bib abs

L16 ANSWER 1 OF 40 USPATFULL
AN 2003:78450 USPATFULL
TI Systematic discovery of new genes and genes discovered thereby
IN Zeng, Qiandong, Belmont, MA, UNITED STATES
Kessler, Marco M., Peabody, MA, UNITED STATES
Cottarel, Guillaume, Arlington, MA, UNITED STATES
PI US 2003054370 A1 20030320
AI US 2002-83357 A1 20020227 (10)
PRAI US 2001-271406P 20010227 (60)
US 2001-333726P 20011129 (60)
DT Utility
FS APPLICATION
LREP BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 5941
AB The present invention is directed to a systematic in silico method to identify new coding sequences, including homologs of coding sequences, in S. cerevisiae and other organisms. The present invention is also directed to novel ORFs and the **proteins** encoded thereby identified using the in silico methods.

L16 ANSWER 2 OF 40 USPATFULL
AN 2003:71358 USPATFULL
TI Constitutively desensitized G **protein**-coupled receptors
IN Barak, Larry S., Durham, NC, UNITED STATES
Oakley, Robert H., Durham, NC, UNITED STATES
Caron, Marc G., Durham, NC, UNITED STATES
Laporte, Stephane A., Outremont, CANADA
Wilbanks, Alyson, Chapel Hill, NC, UNITED STATES
PI US 2003049643 A1 20030313
AI US 2002-54616 A1 20020122 (10)
PRAI US 2001-263406P 20010123 (60)
DT Utility
FS APPLICATION
LREP BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 4934
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to modified G-**protein** coupled receptors (GPCRs). The modified GPCRs of the present invention include GPCRs that have been modified to have altered DRY motifs such that the modified GPCRs are constitutively desensitized. As such, the modified GPCRs of the present invention preferably localize to endocytic vesicles or endosomes in an agonist-independent manner. The invention also relates to methods of screening compounds and sample solutions for GPCR activity using the modified GPCRs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 3 OF 40 USPATFULL
AN 2003:70968 USPATFULL
TI Polymeric conjugates for delivery of MHC-recognized epitopes via **peptide** vaccines
IN Li, Frank Q., Montgomery Village, MD, UNITED STATES
Chu, Yong-Liang, Rockville, MD, UNITED STATES
Qiu, Jian-Tai, Rockville, MD, UNITED STATES
PI US 2003049253 A1 20030313
AI US 2002-62710 A1 20020205 (10)
PRAI US 2001-310498P 20010808 (60)
DT Utility
FS APPLICATION
LREP Supervisor, Patent Prosecution Services, PIPER MARBURY RUDNICK & WOLFE LLP, 1200 Nineteenth Street, N.W., Washington, DC, 20036-2412
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1790
AB A method and **compositions** for modulating an immune system response to an antigen in a mammal are disclosed. The method comprises administering to the mammal a conjugate comprising substantially particle-free **hyaluronic** acid (HA), or a polymer analogue thereof, covalently linked to a **peptide** that comprises a T **cell** epitope, or a plurality of epitopes. Typically, the epitope is defined by a sequence of at least about eight amino acids of the antigen.

L16 ANSWER 4 OF 40 USPATFULL
AN 2003:57931 USPATFULL
TI **Compositions** and methods for non-parenteral delivery of

oligonucleotides
IN Teng, Ching-Leou, San Diego, CA, UNITED STATES
Cook, Phillip Dan, Fallbrook, CA, UNITED STATES
Tillman, Lloyd, Carlsbad, CA, UNITED STATES
Hardee, Gregory E., Rancho Sante Fe, CA, UNITED STATES
Ecker, David J., Encinitas, CA, UNITED STATES
Manoharan, Muthiah, Carlsbad, CA, UNITED STATES
PI US 2003040497 A1 20030227
AI US 2001-29598 A1 20011221 (10)
RLI Continuation of Ser. No. US 1999-315298, filed on 20 May 1999, PENDING
Continuation of Ser. No. US 1998-108673, filed on 1 Jul 1998, PENDING
Continuation-in-part of Ser. No. US 1997-886829, filed on 1 Jul 1997, ABANDONED
DT Utility
FS APPLICATION
LREP Michael P. Straher, Woodcock Washburn LLP, One Liberty Place-46th Floor, Philadelphia, PA, 19103
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3600
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to **compositions** and methods which enhance the local and systemic uptake and delivery of **oligonucleotides** and **nucleic** acids via non-parenteral routes of administration. Pharmaceutical **compositions** comprising **oligonucleotides** disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that **oligonucleotides** may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical **compositions** of **oligonucleotides** may further include one or more penetration enhancers for the transport of **oligonucleotides** and other **nucleic** acids across mucosal **membranes**. The **compositions** and methods of the invention are utilized to effect the oral, buccal, rectal or vaginal administration of an **antisense oligonucleotide** to an animal in order to modulate the expression of a gene in the animal for investigative, therapeutic, palliative or prophylactic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 5 OF 40 USPATFULL
AN 2003:39271 USPATFULL
TI Antimicrobial polypeptides and their uses
IN Altier, Daniel J., Waukee, IA, UNITED STATES
Herrmann, Rafael, Wilmington, DE, UNITED STATES
Lu, Albert L., Newark, DE, UNITED STATES
McCutchen, Billy F., Clive, IA, UNITED STATES
Presnail, James K., Avondale, PA, UNITED STATES
Weaver, Janine L., Bear, DE, UNITED STATES
Wong, James F.H., Johnston, IA, UNITED STATES
PA Pioneer Hi-Bred International, Inc. (U.S. corporation)
PI US 2003028920 A1 20030206
AI US 2002-125258 A1 20020418 (10)
PRAI US 2001-285355P 20010420 (60)
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, PIONEER HI-BRED INTERNATIONAL, INC., BANK OF AMERICA PLAZA, 101 SOUTH TYRON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)

LN.CNT 5402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The methods and **compositions** of the present invention find use in impacting microbial pathogens and in enhancing disease resistance to pathogens, particularly by plants. The **compositions** of the invention include polypeptides that possess antimicrobial properties, particularly fungicidal properties, and the encoding **nucleic** acid molecules. The polypeptides of the invention are isolated from the hemolymph and fat bodies of insect larvae induced by injection of plant pathogenic fungi. Further provided are plant **cells**, plants, and seed thereof, transformed with the **nucleic** acid molecules of the invention so as to confer disease resistance on the plant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 6 OF 40 USPATFULL
AN 2002:273397 USPATFULL
TI Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation
IN Collins, Douglas A., Rochester, MN, UNITED STATES
Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES
PI US 2002151525 A1 20021017
AI US 2001-27593 A1 20011025 (10)
PRAI US 2000-243082P 20001025 (60)
US 2000-243112P 20001025 (60)
DT Utility
FS APPLICATION
LREP KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 4143
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An agent, **composition** and method for the treatment, prophylaxis and/or diagnosis of proliferative disorders, which is highly and efficiently absorbed at the site of abnormal cellular proliferation is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 7 OF 40 USPATFULL
AN 2002:265950 USPATFULL
TI Cationic **polysaccharide compositions** Instant.
IN Domb, Abraham J., Efrat, ISRAEL
PA Polygene Ltd. (non-U.S. corporation)
PI US 2002146826 A1 20021010
AI US 2002-44538 A1 20020110 (10)
PRAI IL 2001-140844 20010110
DT Utility
FS APPLICATION
LREP PATREA L. PABST, HOLLAND & KNIGHT LLP, SUITE 2000, ONE ATLANTIC CENTER, 1201 WEST PEACHTREE STREET, N.E., ATLANTA, GA, 30309-3400
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a polycation **composition** comprising a **polysaccharide** chain having an amount of saccharide units ranging from 2 to 2000, at least one oligoamine directly grafted to said **polysaccharide** chain per each segment of 5 saccharide units, wherein said oligoamine is selected from the group consisting of a linear, branched and cyclic **alkyl** amine having at least two amino groups, and at least one further grafted group selected from the

group consisting of a **hydrophobic** and an **amphiphilic** group directly grafted to said **polysaccharide** chain per each segment of 50 saccharide units, wherein said **hydrophobic** or **amphiphilic** group includes an aliphatic chain of at least 4 carbons atoms.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 8 OF 40 USPATFULL
AN 2002:262078 USPATFULL
TI Tumor delivery vehicles
IN Fick, James R., Martinez, GA, United States
PA FBP Corporation, San Francisco, CA, United States (U.S. corporation)
PI US 6461641 B1 20021008
AI US 1999-243756 19990203 (9)
RLI Continuation of Ser. No. US 1996-690535, filed on 31 Jul 1996, now patented, Pat. No. US 5945100
DT Utility
FS GRANTED
EXNAM Primary Examiner: Nguyen, Dave T.
LREP Holland & Knight LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1033
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The major problem with current direct delivery techniques of therapeutic reagents into solid tumors, especially of **cells** or large volumes of recombinant DNA reagents or drugs, has been resistance of the tissues to the influx of the fluid and/or **cells**, resulting in low quantities of the fluid and/or **cells** penetrating into and remaining in the tumor tissue to be treated. Increased penetration and/or reduced backflow and diversion through the point of entry, so that more material is introduced into and remains in the tumor, is obtained through the use of a viscous vehicle, most preferably having a similar density to tissue, for the material to be delivered. Preferred materials include solutions or suspensions of a polymeric material which gel or solidify at the time of or shortly after injection or implantation. In the preferred embodiment, the solution is injected via a catheter into regions of the tumor to be treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 9 OF 40 USPATFULL
AN 2002:236036 USPATFULL
TI Multifunctional polymeric surface coatings in analytic and sensor devices
IN Hubbell, Jeffrey A., Zumikon, SWITZERLAND
Textor, Marcus, Schaffhausen, SWITZERLAND
Elbert, Donald L., Zurich, SWITZERLAND
Finken, Stephanie, Zurich, SWITZERLAND
Hofer, Rolf, Biel, SWITZERLAND
Spencer, Nicholas D., Zollikon, SWITZERLAND
Ruiz-Taylor, Laurence, Belmont, CA, UNITED STATES
PI US 2002128234 A1 20020912
AI US 2000-560472 A1 20000428 (9)
PRAI US 1999-131391P 19990428 (60)
US 1999-131402P 19990428 (60)
US 2000-184616P 20000224 (60)
DT Utility
FS APPLICATION
LREP Patrea L Pabst, Holland & Knight LLP, Suite 2000 One Atlantic Center, 1201 West Peachtree Street N E, Atlanta, GA, 30309-3400
CLMN Number of Claims: 57

ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 2837
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Multifunctional, polyionic copolymers with molecular architectures and properties optimized for specific applications are synthesized on/or applied to substrate surfaces for analytical and sensing purposes. The coatings are particularly useful for suppression of non-specific interaction, adsorption or attachment of molecular or ionic components present in an analyte solution. Chemical, biochemical or **biological** groups can be coupled to, integrated into or absorbed to the multifunctional polymer that are able to recognize, interact with and bind specifically to target molecules in the material containing the analyte to be detected. These multifunctional polymer coatings are compatible with a variety of different established methods to detect, sense and quantify the target molecule in an analyte. These materials can also be used to modulate **biological** interactions upon substrate surfaces for use as selective implant surfaces that resist **cell** attachment and may optionally promote the attachment of specific **cell** types or induce a particular cellular behavior. The multifunctional polymer coatings typically include brush copolymers based on a polycationic or polyanionic (jointly referred to herein as `polyionic`) backbone with side chains that control interaction with the environment, such as poly(ethylene **glycol**) or poly(ethylene oxide)-based side chains that decrease cellular adhesion, and analyte-specific side chains. Non-modified and modified copolymers can be used singly, consecutively or as a mixture. They can be used to pattern the surfaces into non-adhesive and specifically adhesive areas by applications of known techniques such as microfluidic or contact printing techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 10 OF 40 USPATFULL
AN 2002:217220 USPATFULL
TI Enzymatic cleaning **compositions**
IN Bettiol, Jean-Luc Philippe, Brussels, BELGIUM
Joos, Conny Erna-Alice, Buggenhout, BELGIUM
PA Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 6440911 B1 20020827
WO 9909126 19990225
AI US 2000-485649 20000317 (9)
WO 1998-US11993 19980610
20000317 PCT 371 date
PRAI EP 1997-870120 19970814
DT Utility
FS GRANTED
EXNAM Primary Examiner: Delcotto, Gregory
LREP Cook, C. Brant, Zerby, K. W., Miller, Steve W.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3753
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to cleaning **compositions** a mannanase and a carbohydrase selected from cellulases, amylases, pectin degrading enzymes and/or xyloglucanases. These **compositions** provide superior cleaning performance, i.e. superior stain removal, dingy cleaning and whiteness maintenance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 11 OF 40 USPATFULL

AN 2002:191539 USPATFULL
TI Full-length human cDNAs encoding potentially secreted proteins
IN Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
PI US 2002102604 A1 20020801
AI US 2000-731872 A1 20001207 (9)
PRAI US 1999-169629P 19991208 (60)
US 2000-187470P 20000306 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., Genset Corporation, 10665 Srrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 28061
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 12 OF 40 USPATFULL
AN 2002:175117 USPATFULL
TI Detergent **compositions** comprising a mannanase and a bleach system
IN Bettiol, Jean-Luc Philippe, Brussels, BELGIUM
Showell, Michael Stanford, Cincinnati, OH, United States
Baeck, Andre Cesar, Bonheiden, BELGIUM
Thoen, Christiaan Arthur Jacques Kamiel, West Chester, OH, United States
PA Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 6420331 B1 20020716
AI US 2000-503565 20000214 (9)
RLI Continuation-in-part of Ser. No. WO 1998-US12023, filed on 10 Jun 1998, now abandoned Continuation-in-part of Ser. No. WO 1998-US12024, filed on 10 Jun 1998, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Gupta, Yogendra N.; Assistant Examiner: Elhilo, Eisa
LREP Cook, C. Brant, Zerby, K. W., Miller, Steve W.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3669
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to detergent **compositions** comprising a mannasase enzyme and a bleach system preferably comprising a source of hydrogen peroxide and optionally, but preferably, a **hydrophobic** bleach activator for superior cleaning, stain removal and/or whiteness performance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 13 OF 40 USPATFULL
AN 2002:157632 USPATFULL
TI Cationic polymers and lipids for the delivery of **nucleic** acids
IN Sullivan, Sean M., The Woodlands, TX, UNITED STATES

Meng, Xiao-Ying, Mountain View, CA, UNITED STATES
PI US 2002082237 A1 20020627
AI US 2002-84159 A1 20020228 (10)
RLI Continuation of Ser. No. US 1997-865375, filed on 29 May 1997, ABANDONED
PRAI US 1996-18377P 19960529 (60)
DT Utility
FS APPLICATION
LREP ROYLANCE, ABRAMS, BERDO & GOODMAN, L.L.P., 1300 19TH STREET, N.W., SUITE 600, WASHINGTON,, DC, 20036
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1266
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel cationic polymers and cationic lipids, and methods of making and using the same, are provided. The cationic polymers and cationic lipids are useful for the delivery of **nucleic** acid polymers and oligomers to **cells** in vitro and in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 14 OF 40 USPATFULL
AN 2002:106270 USPATFULL
TI **Antisense** modulation of PTP1B expression
IN Cowsert, Lex M., San Mateo, CA, UNITED STATES
Wyatt, Jacqueline, Encinitas, CA, UNITED STATES
Freier, Susan M., San Diego, CA, UNITED STATES
Monia, Brett P., La Costa, CA, UNITED STATES
Butler, Madeline M., Rancho Santa Fe, CA, UNITED STATES
McKay, Robert, San Diego, CA, UNITED STATES
PI US 2002055479 A1 20020509
AI US 2001-854883 A1 20010514 (9)
RLI Continuation-in-part of Ser. No. US 2000-629644, filed on 31 Jul 2000, PENDING Continuation-in-part of Ser. No. US 2000-487368, filed on 18 Jan 2000, GRANTED, Pat. No. US 6261840
DT Utility
FS APPLICATION
LREP HOWSON AND HOWSON, Spring House Corporate, Box 457, Spring House, PA, 19477
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6714
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds, **compositions** and methods are provided for modulating the expression of PTP1B. The **compositions** comprise **antisense** compounds, particularly **antisense oligonucleotides**, targeted to **nucleic** acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 15 OF 40 USPATFULL
AN 2002:92631 USPATFULL
TI Cobalamin compounds useful as cardiovascular agents and as imaging agents
IN Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES
PI US 2002049155 A1 20020425
AI US 2001-873142 A1 20010531 (9)
PRAI US 2000-208140P 20000531 (60)
US 2001-267782P 20010209 (60)
DT Utility

FS APPLICATION
LREP KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 4521
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides cobalamin derivatives linked to a cardiovascular agent, as well as pharmaceutical **compositions** comprising the compounds and methods for using the compounds in treatment or diagnosis of a cardiovascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 16 OF 40 USPATFULL
AN 2002:88439 USPATFULL
TI Detergent **compositions** comprising a mannanase and a protease
IN Bettiol, Jean-Luc Philippe, Brussels, BELGIUM
Showell, Michael Stanford, Cincinnati, OH, United States
PA Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 6376445 B1 20020423
WO 9909128 19990225
AI US 2000-485648 20000405 (9)
WO 1998-US11996 19980610
20000405 PCT 371 date
PRAI EP 1997-870120 19970814
DT Utility
FS GRANTED
EXNAM Primary Examiner: Delcotto, Gregory
LREP Taffy, Frank, Zerby, K. W., Miller, Steve W.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Detergent **compositions** for cleansing fabrics, dishware and hard surfaces contain a mannanase enzyme, a protease enzyme and detersive ingredients. Mannanase enzymes from Bacillus agaradherens and Bacillus subtilisis strain 168, gene yght, as well as isolated polypeptides therefrom, are used to remove stains.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 17 OF 40 USPATFULL
AN 2002:78737 USPATFULL
TI Cobalamin compounds useful as antibiotic agents and as imaging agents
IN Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES
Collins, Douglas A., Rochester, MN, UNITED STATES
PI US 2002042394 A1 20020411
AI US 2001-873164 A1 20010531 (9)
PRAI US 2000-208148P 20000531 (60)
US 2001-267543P 20010209 (60)
DT Utility
FS APPLICATION
LREP KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 4896
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides cobalamin derivatives linked to an antibiotic and/or an imaging agent, as well as pharmaceutical **compositions** comprising the compounds and methods for using the compounds in

treatment or diagnosis of a microbial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 18 OF 40 USPATFULL
AN 2002:37547 USPATFULL
TI Delivery vehicles comprising stable lipid/**nucleic** acid complexes
IN Sullivan, Sean M., Danville, CA, UNITED STATES
Hofland, Hans, San Francisco, CA, UNITED STATES
PI US 2002022264 A1 20020221
AI US 2001-809292 A1 20010316 (9)
RLI Continuation of Ser. No. US 1996-652018, filed on 21 May 1996, ABANDONED Continuation-in-part of Ser. No. US 1995-450142, filed on 26 May 1995, ABANDONED
DT Utility
FS APPLICATION
LREP ROYLANCE, ABRAMS, BERRO & GOODMAN, L.L.P., 1300 19TH STREET, N.W., SUITE 600, WASHINGTON,, DC, 20036
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 1766
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Stable polynucleotide delivery vehicles (SPDVs) are described which incorporate a polynucleotide/cationic lipid complex as structural components of the SPDV. The subject SPDVs may optionally incorporate synthetic **biodegradable** amphipathic lipids, and suitable targeting agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 19 OF 40 USPATFULL
AN 2002:22163 USPATFULL
TI Cationic liposomes
IN Gonda, Igor, San Francisco, CA, UNITED STATES
Margalit, Rimona, Tel Aviv, ISRAEL
PI US 2002012998 A1 20020131
AI US 2001-823256 A1 20010329 (9)
PRAI US 2000-193062P 20000329 (60)
DT Utility
FS APPLICATION
LREP Paula Borden, BOZICEVIC, FIELD & FRANCIS LLP, 200 Middlefield Road, Suite 200, Menlo Park, CA, 94025
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1148
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The cationic liposomal formulations of the present invention provide **nucleic** acid and gene product delivery devices having a glycosaminoglycan covalently attached to the liposome surface. The glycosaminoglycan can be any glycosaminoglycan, including but not limited to **hyaluronic** acid, the chondroitin sulfates, keratan sulfate, chitin and heparin. Preferably, the glycosaminoglycan is **hyaluronic** acid. The present invention also provides methods of preparing the **nucleic** acid-liposome formulations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 20 OF 40 USPATFULL
AN 2001:235126 USPATFULL
TI Hydrogel **compositions** for controlled delivery of virus vectors and methods of use thereof

IN Levy, Robert J., Merion Station, PA, United States
Crombleholme, Timothy, Haverford, PA, United States
Vyavahare, Narendra, Erial, NJ, United States
PA The Children's Hospital of Philadelphia, Philadelphia, PA, United States (U.S. corporation)
PI US 6333194 B1 20011225
AI US 2000-487854 20000119 (9)
PRAI US 1999-116538P 19990119 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wang, Andrew; Assistant Examiner: Zara, Jane
LREP Foley & Lardner
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 3154
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to **compositions** and methods for delivering a virus vector to an animal. The **compositions** include **compositions** which comprise a hydrogel matrix (e.g. a collagen matrix which can comprise a poloxamer or an **alginate**) containing a virus vector therein in a **transfectious** form. The invention also includes methods of making such hydrogel precursor mixtures and hydrogel matrices, including particles, devices, bulk materials, and other objects which comprise, consist of, or are coated with such mixtures or matrices. The invention further relates to **compositions** comprising a hydrogel precursor mixture having a virus vector suspended therein, which, when administered to an animal, gel to form a hydrogel matrix containing a virus vector therein in a **transfectious** form. Methods of delivering a virus vector to an animal tissue are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 21 OF 40 USPATFULL
AN 2001:212417 USPATFULL
TI In situ bioreactors and methods of use thereof
IN Pierce, Glenn, Rancho Santa Fe, CA, United States
Chandler, Lois Ann, Encinitas, CA, United States
PI US 2001044413 A1 20011122
AI US 2000-729644 A1 20001130 (9)
PRAI US 1999-168470P 19991201 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 104
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 2302
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides in situ bioreactors comprising a biocompatible substance comprising **nucleic** acid molecules and capable of cellular ingrowth and systemic delivery of a bioactive agent. Also provided are **compositions**, devices, and kits comprising the same. In various embodiments the biocompatible substance comprises a matrix and at least one **nucleic** acid molecule encoding a bioactive agent. In other embodiments bioreactors are provided wherein a first gene that encodes a growth factor is present and a second gene encoding a bioactive agent is present during manufacture or provided to the bioreactor following manufacture or implantation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 22 OF 40 USPATFULL
AN 2001:212416 USPATFULL
TI **Compositions** and methods for drug delivery using **amphiphile** binding molecules
IN Wolff, Jon A., Madison, WI, United States
Hagstrom, James E., Madison, WI, United States
Monahan, Sean D., Madison, WI, United States
Budker, Vladimir, Middleton, WI, United States
Rozema, David B., Madison, WI, United States
Slatum, Paul M., Madison, WI, United States
PI US 2001044412 A1 20011122
AI US 2000-726792 A1 20001129 (9)
RLI Continuation-in-part of Ser. No. US 1999-234606, filed on 21 Jan 1999, PENDING
PRAI US 1999-167836P 19991129 (60)
DT Utility
FS APPLICATION
LREP Mark K. Johnson, PO Box 510644, New Berlin, WI, 53151-0644
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2085
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the delivery of desired compounds (e.g., **nucleic** acids) into **cells** using noncovalent delivery systems which include complexing **nucleic** acids, amphipathic binding agents, and **amphiphiles**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 23 OF 40 USPATFULL
AN 2001:212153 USPATFULL
TI Delivery vehicles comprising stable lipid/**nucleic** acid complexes
IN Sullivan, Sean M., Danville, CA, United States
Hofland, Hans, San Francisco, CA, United States
PI US 2001044147 A1 20011122
AI US 2001-855796 A1 20010516 (9)
RLI Continuation of Ser. No. US 1996-652018, filed on 21 May 1996, PENDING
Continuation-in-part of Ser. No. US 1995-450142, filed on 26 May 1995, ABANDONED
DT Utility
FS APPLICATION
LREP Roylance, Abrams, Berdo & Goodman, L.L.P., Suite 600, 1300 19th Street, N.W., Washington, DC, 20036
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 1766
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Stable polynucleotide delivery vehicles (SPDVs) are described which incorporate a polynucleotide/cationic lipid complex as structural components of the SPDV. The subject SPDVs may optionally incorporate synthetic **biodegradable** amphipathic lipids, and suitable targeting agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 24 OF 40 USPATFULL
AN 2001:196635 USPATFULL
TI Delivery of **nucleic** acid materials
IN Schacht, Etienne H, Rijsseveldstraat 99, B-8140, Staden, Belgium
Seymour, Leonard C W, The University of Birmingham, Clinical Research Block, The Medical School, Edgbaston, Birmingham B15 2TJ, United Kingdom

Ulbrich, Karel, Inst of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovsky Sq. 2, 16206, Prague 7, Czech Republic
PI US 6312727 B1 20011106
AI US 1999-306568 19990506 (9)
RLI Continuation of Ser. No. WO 1997-GB2965, filed on 6 Nov 1997
PRAI GB 1996-23051 19961106
DT Utility
FS GRANTED
EXNAM Primary Examiner: McKelvey, Terry; Assistant Examiner: Sandals, William
LREP Pillsbury Winthrop LLP
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2173
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Synthetic polymer-based carrier vehicles for delivery of **nucleic** acid material to target **cells** in **biological** systems are made by self-assembly of the **nucleic** acid with cationic polymer material so as to condense the **nucleic** acid and form a polyelectrolyte complex and reacting the complex with hydrophilic polymer material which bonds to the complex forming a hydrophilic coating that stabilizes the complex and provides an outer protective steric shield. The carrier vehicles are useful for gene therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 25 OF 40 USPATFULL
AN 2001:182086 USPATFULL
TI Novel methods of ultrasound treatment using gas or gaseous precursor-filled **compositions**
IN Unger, Evan C., Tucson, AZ, United States
PA ImaRx Pharmaceutical Corp. (U.S. corporation)
PI US 2001031243 A1 20011018
AI US 2001-813484 A1 20010321 (9)
RLI Division of Ser. No. US 1997-929847, filed on 15 Sep 1997, PENDING
DT Utility
FS APPLICATION
LREP Woodcock Washburn Kurtz, Mackiewicz & Norris LLP, 46th Floor, One Liberty Place, Philadelphia, PA, 19103
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6360
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes, among other things, the surprising discovery that gaseous precursor filled **compositions** are profoundly more effective as acoustically active contrast agents when they are thermally preactivated to temperatures at or above the boiling point of the instilled gaseous precursor prior to their in vivo administration to a patient. Further optimization of contrast enhancement is achieved by administering the gaseous precursor filled **compositions** to a patient as an infusion. Enhanced effectiveness is also achieved for ultrasound mediated targeting and drug delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 26 OF 40 USPATFULL
AN 2001:109889 USPATFULL
TI CATIONIC POLYMERS AND LIPIDS FOR THE DELIVERY OF **NUCLEIC** ACIDS
IN SULLIVAN, SEAN M., DANVILLE, CA, United States
MENG, XIAO-YING, ALAMEDA, CA, United States
PI US 2001007771 A1 20010712
AI US 1997-865375 A1 19970529 (8)
PRAI US 1996-18377P 19960529 (60)

DT Utility
FS APPLICATION
LREP DEAN H. NAKAMURA, ESQUIRE, ROYLANCE, ABRAMS, BERDO AND GOODMAN, LLP, 1300 19TH STREET, N.W., SUITE 600, WASHINGTON, DC, 20036
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel cationic polymers and cationic lipids, and methods of making and using the same, are provided. The cationic polymers and cationic lipids are useful for the delivery of **nucleic** acid polymers and oligomers to **cells** in vitro and in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 27 OF 40 USPATFULL
AN 2001:102621 USPATFULL
TI **Antisense** modulation of Her-4 expression
IN Bennett, C. Frank, Carlsbad, CA, United States
Cowsert, Lex M., Carlsbad, CA, United States
PA Isis Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)
PI US 6255111 B1 20010703
AI US 2000-632580 20000731 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: McGarry, Sean
LREP Licata & Tyrrell P.C.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2555
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Antisense** compounds, **compositions** and methods are provided for modulating the expression of Her-4. The **compositions** comprise **antisense** compounds, particularly **antisense oligonucleotides**, targeted to **nucleic** acids encoding Her-4. Methods of using these compounds for modulation of Her-4 expression and for treatment of diseases associated with expression of Her-4 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 28 OF 40 USPATFULL
AN 2001:36655 USPATFULL
TI **Antisense** inhibition of SHP-2 expression
IN Bennett, C. Frank, Carlsbad, CA, United States
Cowsert, Lex M., Carlsbad, CA, United States
PA Isis Pharmaceuticals Inc., Carlsbad, CA, United States (U.S. corporation)
PI US 6200807 B1 20010313
AI US 1999-358683 19990721 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Elliott, George C.; Assistant Examiner: Zara, Jane
LREP Law Offices of Jane Massey Licata
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2592
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Antisense** compounds, **compositions** and methods are provided for modulating the expression of SHP-2. The

compositions comprise **antisense** compounds, particularly **antisense oligonucleotides**, targeted to **nucleic** acids encoding SHP-2. Methods of using these compounds for modulation of SHP-2 expression and for treatment of diseases associated with expression of SHP-2 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 29 OF 40 USPATFULL
AN 2000:127960 USPATFULL
TI Optoacoustic contrast agents and methods for their use
IN Unger, Evan C., Tucson, AZ, United States
Wu, Yunqiu, Tucson, AZ, United States
PA Imarx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PI US 6123923 20000926
AI US 1997-993165 19971218 (8)
PRAI US 1997-46379P 19970513 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Sharareh, Shahnam
LREP Woodcock Washburn Kurtz Mackiewcz & Norris LLP
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 6923
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention generally relates to optoacoustic contrast agents and methods of diagnostic and therapeutic imaging using optoacoustic contrast agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 30 OF 40 USPATFULL
AN 2000:124825 USPATFULL
TI **Antisense** modulation of SHP-1 expression
IN Bennett, C. Frank, Carlsbad, CA, United States
Cowsert, Lex M., Carlsbad, CA, United States
PA Isis Pharmaceuticals Inc., Carlsbad, CA, United States (U.S. corporation)
PI US 6121047 20000919
AI US 1999-358685 19990721 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Elliott, George C.; Assistant Examiner: Schmidt, Melissa
LREP Law Offices of Jane Massey Licata
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3015
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Antisense** compounds, **compositions** and methods are provided for modulating the expression of SHP-1. The **compositions** comprise **antisense** compounds, particularly **antisense oligonucleotides**, targeted to **nucleic** acids encoding SHP-1. Methods of using these compounds for modulation of SHP-1 expression and for treatment of diseases associated with expression of SHP-1 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 31 OF 40 USPATFULL
AN 2000:97989 USPATFULL
TI Method to enhance treatment of cystic tumors

IN Fick, James R., Martinez, GA, United States
PA Medical College of Georgia Research Institute, Inc., Augusta, GA, United States (U.S. corporation)
PI US 6096303 20000801
AI US 1997-904097 19970731 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Schwartzman, Robert A.
LREP Arnall Golden & Gregory, LLP
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1429
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB It has been discovered that **cells** such as genetically engineered fibroblasts and keratinocytes can be cultured in the cyst fluid of encapsulated tumors. This provides a means for proliferating genetically engineered producer **cells** within these types of tumors, increasing the number of **cells** producing viral particles, which then transduce the surrounding tumor **cells** with the genetic material, in the preferred embodiment, a lethal gene. A number of different tumor types form "cysts", which contain fluid produced by the tumor **cells**, including brain tumor **cells** such as gliomas, and many types of breast, and lung tumors. These cyst fluids have been shown to contain elevated levels of certain growth factors, for example, fibroblast growth factor (FGF) and epidermal growth factor (EGF). The types of genetically engineered **cells** to be used can be selected in part according to the levels of growth factors in the cyst fluid which most promote growth of the **cells**, for example, cystic tumors with high levels of FGF would be injected with genetically engineered fibroblasts; cystic tumors with high levels of EGF would be injected with genetically engineered keratinocytes; and cystic tumors with high levels of vascular endothelial growth factor (VEGF) would be injected with genetically engineered endothelial **cells**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 32 OF 40 USPATFULL
AN 2000:31250 USPATFULL
TI **Antisense** inhibition of integrin beta 3 expression
IN Bennett, C. Frank, Carlsbad, CA, United States
Monia, Brett P., La Costa, CA, United States
Cowsert, Lex M., Carlsbad, CA, United States
PA Isis Pharmaceuticals Inc., Carlsbad, CA, United States (U.S. corporation)
PI US 6037176 20000314
AI US 1999-344520 19990625 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: LeGuyader, John L.
LREP Law Offices of Jane Massey Licata
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2912
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Antisense** compounds, **compositions** and methods are provided for modulating the expression of integrin beta 3. The **compositions** comprise **antisense** compounds, particularly **antisense oligonucleotides**, targeted to **nucleic** acids encoding integrin beta 3. Methods of using these compounds for modulation of integrin beta 3 expression and for treatment of diseases associated with expression of integrin beta 3 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 33 OF 40 USPATFULL
AN 2000:21560 USPATFULL
TI Prodrugs comprising fluorinated **amphiphiles**
IN Unger, Evan C., Tucson, AZ, United States
PA Imarx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PI US 6028066 20000222
AI US 1997-887215 19970702 (8)
RLI Continuation-in-part of Ser. No. US 1997-851780, filed on 6 May 1997
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Badio, Barbara
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes, inter alia, novel prodrugs comprising fluorinated **amphiphiles**, **compositions** comprising the novel prodrugs, and methods of use of the prodrugs and **compositions**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 34 OF 40 USPATFULL
AN 1999:102490 USPATFULL
TI Tumor delivery vehicles
IN Fick, James R., Martinez, GA, United States
PA FBP Corporation, San Francisco, CA, United States (U.S. corporation)
PI US 5945100 19990831
AI US 1996-690535 19960731 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Campell, Bruce R.; Assistant Examiner: Nguyen, Dave Trong
LREP Arnall Golden & Gregory, LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 970
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The major problem with current direct delivery techniques of therapeutic reagents into solid tumors, especially of **cells** or large volumes of recombinant DNA reagents or drugs, has been resistance of the tissues to the influx of the fluid and/or **cells**, resulting in low quantities of the fluid and/or **cells** penetrating into and remaining in the tumor tissue to be treated. Increased penetration and/or reduced backflow and diversion through the point of entry, so that more material is introduced into and remains in the tumor, is obtained through the use of a viscous vehicle, most preferably having a similar density to tissue, for the material to be delivered. Preferred materials include solutions or suspensions of a polymeric material which gel or solidify at the time of or shortly after injection or implantation. In the preferred embodiment, the solution is injected via a catheter into regions of the tumor to be treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 35 OF 40 USPATFULL
AN 1998:119169 USPATFULL
TI Selective prevention of organ injury is sepsis and shock using selective

release of nitric oxide vulnerable organs
IN Saavedra, Joseph E., Thurmont, MD, United States
Keefer, Larry K., Bethesda, MD, United States
PA The United States Of America, as represented by the Department Of Health And Human Services, Washington, DC, United States (U.S. corporation)
PI US 5814656 19980929
AI US 9428968 19971002 (8)
RLI Division of Ser. No. 509558, filed on 31 Jul 1995, now patented, Pat. No. 5714511
DT Utility
FS Granted
EXNAM Primary Examiner: Henley, III, Raymond
LREP Leydig, Voit & Mayer, Ltd.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1003
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the treatment of mammalian tissue injured or at risk of injury during sepsis or shock including the administration to a mammal a diazeniumdiolate which releases a therapeutically effective amount of nitric oxide sufficient to protect the tissue from sepsis- or shock-induced injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 36 OF 40 USPATFULL
AN 1998:12052 USPATFULL
TI Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
IN Saavedra, Joseph E., Thurmont, MD, United States
Keefer, Larry K., Bethesda, MD, United States
Billiar, Timothy R., Pittsburgh, PA, United States
PA The United States of America as represented by the Secretary of the Department of Health and Human Services, Washington, DC, United States (U.S. government)
The University of Pittsburgh, Pittsburgh, PA, United States (U.S. corporation)
PI US 5714511 19980203
AI US 1995-509558 19950731 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Henley, III, Raymond
LREP Leydig, Voit & Mayer, Ltd.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1646
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the treatment of mammalian tissue injured or at risk of injury during sepsis or shock including the administration to a mammal a diazeniumdiolate which releases a therapeutically effective amount of nitric oxide sufficient to protect the tissue from sepsis- or shock-induced injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> dis hist

     (FILE 'HOME' ENTERED AT 10:28:06 ON 01 APR 2003)

     FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, EMA, IFIPAT, JICST-EPLUS,
     PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL,
     USPAT2, WPINDEX, WTEXTILES' ENTERED AT 10:28:22 ON 01 APR 2003
L1      4583415 S COMPOSITION
L2        26461 S L1 AND (POLYSACCHARIDE AND ?AMINE)
L3         3258 S L1 AND (POLYSACCHARIDE AND POLYAMINE)
L4         2816 S L3 AND (ALKYL OR HYDROPHOB? OR AMPHIPHIL?)
L5         1815 S L4 AND (NUCLEIC OR PROTEIN)
L6         1616 S L5 AND (DEXTRAN OR ARABINOGALACTAN OR PULLULAN OR CELLULOSE
L7          559 S L6 AND (SPERMINE OR SPERMIDINE OR POLYETHYLENEIMINE)
L8          405 S L7 AND (BIOLOGICAL OR MEMBRANE)
L9          255 S L8 AND BIODEGRA?
L10         245 S L9 AND (CELL OR TRANSFECT?)
L11         220 S L10 AND PEPTIDE
L12         204 S L11 AND (POLYNUCLEIC OR OLIGONUCLEOTIDE OR ANTISENSE)
L13         203 S L12 AND (FATTY OR OLEIC OR GLYCOL)
L14          40 S L13 AND (TOXIC OR IMMUNOG?)

     INDEX 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, EMA, IFIPAT, JICST-EPLUS,
     PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL,
     USPAT2, WPIDS, WPINDEX, WTEXTILES' ENTERED AT 10:43:00 ON 01 APR 2003
                SEA L14
               ---------
              40   FILE USPATFULL
L15             QUE L14
               ---------

     FILE 'USPATFULL' ENTERED AT 10:45:45 ON 01 APR 2003
L16          40 S L14
```